drugset / Trial / NCT05227131
Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, single-arm, phase II clinical trial to evaluate the efficacy and safety of margetuximab in combination with tucatinib and capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Timeline
- Start
- 2022-05-15
- Primary completion
- 2024-10
- Completion
- 2024-10
Outcome
Outcome not reported
Stopped (Business): “Funder decided to not continue the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Margetuximab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Background | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Background | Tucatinib | Small molecule | 300 mg | Oral |